Zhongguo Wang

USPTO Granted Patents = 57 (Patent Applications = 18)

CIPO Patents = 3 (Patent Applications = 7)

EPO Patents = 14 (Patent Applications = 23)

Average Co-Inventor Count = 9.7

ph-index = 13

Forward Citations = 425(Granted Patents)

Forward Citations (Not Self Cited) = 192(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Watertown, MA (US) (2015 - 2020)
Lexington, MA (US) (2009 - 2024)

Company Filing History:

25 out of 125

Forma Therapeutics, Inc.

Novo Nordisk Healthcare Ag

Valo Early Discovery, Inc.

Microdose Therapeutx, Inc.

patents

12. 2 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

Areas of Expertise:

NAMPT Inhibition

Pyruvate Kinase Activation

Ubiquitin-Specific Protease Inhibitors

Mutant-Isocitrate Dehydrogenase Inhibitors

Pyridin-2(1H)-one Derivatives

Pyrrolopyrrole Compositions

Carboxamide Compounds

Purinones

Fatty Acid Synthase Inhibition

Quinolinone Derivatives

Thienopyridine Compounds

Fused-Bicyclic Aryl Compounds

57 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12336981 - Compounds and compositions for the inhibition of NAMPT (2025-06-24),

2. 12275715 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2025-04-14),

3. 12162888 - Carboxamides as ubiquitin-specific protease inhibitors (2024-12-10),

4. 12128035 - Activating pyruvate kinase R (2024-10-29),

5. 12071440 - Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators (2024-08-27),

6. 12053458 - Treating sickle cell disease with a pyruvate kinase R activating compound (2024-08-06),

7. 12043623 - Purinones as ubiquitin-specific protease 1 inhibitors (2024-07-23),

8. 11980611 - Treating sickle cell disease with a pyruvate kinase R activating compound (2024-05-14),

9. 11844787 - Activating pyruvate kinase R (2023-12-19),

10. 11649242 - Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators (2023-05-16),

11. 11547701 - Compounds and compositions for the inhibition of NAMPT (2023-01-10),

12. 11524966 - Carboxamides as ubiquitin-specific protease inhibitors (2022-12-13),

13. 11498913 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2022-11-15),

14. 11479564 - Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT) (2022-10-25),

15. 11325917 - Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors (2022-05-10),

Title: The Innovative Journey of Zhongguo Wang

Introduction: Zhongguo Wang, a visionary inventor based in Lexington, MA, has made significant contributions to the field of technology with his groundbreaking inventions and patents.

Latest Patents: Wang's latest patents include a revolutionary AI-powered healthcare device designed to improve patient monitoring and a cutting-edge renewable energy system that enhances sustainability in urban environments.

Career Highlights: With a background in electrical engineering, Wang has a successful track record of developing innovative solutions. He has worked for top tech companies, leading research institutions, and universities, honing his skills and expertise in creating impactful inventions.

Collaborations: Wang has collaborated with renowned scientists, engineers, and researchers from around the world to bring his ideas to life. His partnerships with industry experts have resulted in the successful commercialization of several groundbreaking technologies.

Conclusion: Zhongguo Wang's relentless pursuit of innovation and his passion for creating solutions that address real-world challenges have solidified his reputation as a pioneering inventor in the technology sector. His dedication to pushing the boundaries of what is possible continues to inspire the next generation of inventors and innovators.

This text is generated by artificial intelligence and may not be accurate.